from NFL BIOSCIENCES (EPA:ALNFL)
NFL BIOSCIENCES: PARTICIPATION CALENDAR PHARMA EVENTS AND INSTITUTIONAL INVESTORS
COMMUNIQUÉ DE PRESSE
Biosciences
Montpellier, September 9, 2024 - 5:45pm
NFL BIOSCIENCES: PARTICIPATION CALENDAR PHARMA EVENTS AND INSTITUTIONAL INVESTORS
NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XTO - ALNFL), biopharmaceutical company developing botanical drugs for the treatment of addictions, presents its calendar of events with pharmaceutical companies and institutional investors for the 2nd half of 2024.
| Dates* |
International Partnering in Life-Sciences Society (IPLS) Annual Conference (Malaga, Spain) |
|
European Midcap Event (Paris, France) | I & 2 october 2024 |
Events
Seminar Portzamparc Biotech and Healthcare 9 october 2024
*The calendar is provided for information only and may be subject to change.
A propos de NFL Biosciences
NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences l ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easyto-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.
The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL). Find out more at www.nflbiosciences.com
Contacts
Bruno Lafont -info@nflbiosciences.com - 04 Il 93 76 67 Agence Calyptus - nflbio@calyptus.net - 01 53 65 68 68
1